Renal Cell Carcinoma (RCC) Cell Models for Research

Renal cell carcinoma (RCC) accounts for approximately 90% of all kidney cancers, with an estimated 434,840 new cases and 155,703 deaths worldwide in 2022 (WHO GLOBOCAN). The incidence has been rising steadily over the past decades, partly due to increased incidental detection through imaging. Major risk factors include smoking, obesity, hypertension, and inherited syndromes such as von Hippel-Lindau (VHL) disease. The 5-year survival rate for localized RCC is around 93%, but it drops dramatically to 15% for metastatic disease (NCI SEER). This stark contrast underscores the urgent need for better therapeutic strategies and predictive biomarkers.

RCC is an ideal model for studying tumor metabolism, hypoxia signaling, and immune evasion. The disease is characterized by distinct histological subtypes (clear cell, papillary, chromophobe) with unique genetic drivers. Public datasets such as TCGA-KIRC, TCGA-KIRP, and TCGA-KICH provide comprehensive genomic, transcriptomic, and clinical data. Key open questions include the role of epigenetic modifiers in tumor progression, mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, and the identification of synthetic lethal vulnerabilities. Gene-edited cell models allow researchers to dissect these mechanisms with precision.

The pathogenesis of clear cell RCC (ccRCC) is largely driven by loss of function of the VHL tumor suppressor, leading to constitutive activation of hypoxia-inducible factors (HIFs). The following steps outline the canonical pathway:

1. Biallelic inactivation of VHL (mutation, deletion, or promoter hypermethylation) occurs in up to 90% of sporadic ccRCC.

2. Loss of VHL function prevents ubiquitination and degradation of HIF-1α and HIF-2α.

3. Stabilized HIFs translocate to the nucleus and upregulate target genes involved in angiogenesis (VEGF), glycolysis (GLUT1, PDK1), and cell proliferation (TGFα, PDGF).

4. Chronic HIF activation promotes tumor growth, vascularization, and metabolic reprogramming.

In papillary RCC (pRCC), activation of the MET proto-oncogene (mutations or copy number gains) is a key driver, while chromophobe RCC (chRCC) often exhibits mitochondrial DNA alterations and chromosomal losses.

The following table summarizes the most frequently altered genes in RCC, based on TCGA and COSMIC data:

Beyond the VHL/HIF axis, several signaling networks are constitutively active in RCC:

• • PI3K/AKT/mTOR pathway: Frequently activated due to PTEN loss or mTOR mutations; promotes cell growth and survival.
• • MAPK/ERK pathway: Activated by MET mutations in pRCC and by growth factor receptor signaling in ccRCC.
• • Wnt/β-catenin pathway: Aberrant activation contributes to epithelial-mesenchymal transition (EMT) and invasion.
• • Immune checkpoint pathways: Upregulation of PD-L1 on tumor cells and infiltration of regulatory T cells (Tregs) create an immunosuppressive microenvironment.

Key nodes for therapeutic targeting include HIF-2α (e.g., belzutifan), VEGFR (sunitinib, pazopanib), mTOR (everolimus), and PD-1 (nivolumab).

Commonly used RCC cell lines and their key mutations are listed below:

Patient-derived organoids (PDOs) retain the genetic heterogeneity of the original tumor and are increasingly used for drug sensitivity testing. However, they require complex culture conditions and have limited scalability compared to cell lines.

Animal models are essential for studying RCC in vivo. Key models include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice; preserves tumor heterogeneity but lacks immune system.
• • Genetically engineered mouse models (GEMM): Conditional Vhl knockout combined with PBRM1 or BAP1 loss recapitulates ccRCC development.
• • Syngeneic models: RENCA cells injected into Balb/c mice provide an immunocompetent model for testing immunotherapies.
• • Orthotopic models: Injection of tumor cells into the renal capsule mimics the natural tumor microenvironment.

These models are valuable for preclinical validation of drug candidates and for studying tumor-immune interactions.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. These models are crucial for studying the functional impact of specific genetic alterations in RCC. Examples include:

• • VHL knockout in 786-O or Caki-1 cells to study HIF pathway activation.
• • PBRM1 knockout to investigate chromatin remodeling and response to immune checkpoint inhibitors.
• • SETD2 knockout to explore genomic instability and sensitivity to DNA-damaging agents.
• • TP53 knockout to model loss of tumor suppressor function in drug resistance.

Commercially available, sequence-verified gene-edited cell lines (from sources such as those offering CRISPR services) provide researchers with ready-to-use tools, accelerating drug discovery and functional genomics studies. These models are quality-controlled and validated for the intended genetic modification.

Gene-edited cell lines are instrumental in functional genomics to determine the role of specific genes in RCC biology. For example:

• • VHL knockout in 786-O cells confirms the role of VHL in HIF regulation and angiogenesis.
• • PBRM1 knockout in Caki-1 cells demonstrates its tumor suppressor function and impact on gene expression.
• • SETD2 knockout in RCC4 cells reveals its role in homologous recombination repair and sensitivity to PARP inhibitors.

These models allow researchers to perform gain-of-function and loss-of-function studies in a controlled genetic background, facilitating the identification of novel therapeutic targets.

Isogenic cell line pairs (e.g., parental vs. gene-edited) are powerful tools for drug screening and resistance studies. For instance:

• • VHL-deficient cells are hypersensitive to HIF-2α inhibitors, providing a platform for testing new compounds.
• • PBRM1 knockout cells show altered response to immune checkpoint inhibitors, helping to identify predictive biomarkers.
• • Chronic exposure of RCC cells to TKIs (e.g., sunitinib) can generate resistant sublines; CRISPR editing can then be used to identify genes responsible for resistance.

These approaches enable the development of combination therapies and personalized treatment strategies.

CRISPR-based synthetic lethality screens in RCC cell lines can identify genes that are essential only in the context of specific mutations. For example:

• • In VHL-deficient cells, screening for genes whose knockout is lethal can reveal new vulnerabilities, such as HIF-2α or its downstream targets.
• • In BAP1-mutant cells, synthetic lethal partners may include genes involved in DNA repair or chromatin remodeling.

These screens provide a rational basis for developing targeted therapies and companion diagnostics.

The following public databases provide valuable genomic, transcriptomic, and functional data for RCC research: